StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Net Cash Used Provided By Financing Activities for the year ending July 31, 2024: USD 526.70 K

StemRIM Net Cash Used Provided By Financing Activities is USD 526.70 K for the year ending July 31, 2024, a -63.00% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

StemRIM Net Cash Used Provided By Financing Activities for the year ending July 31, 2023 was USD 1.42 M, a 68.11% change year over year.
StemRIM Net Cash Used Provided By Financing Activities for the year ending July 31, 2022 was USD 846.89 K, a -15.01% change year over year.
StemRIM Net Cash Used Provided By Financing Activities for the year ending July 31, 2021 was USD 996.42 K, a -98.64% change year over year.
StemRIM Net Cash Used Provided By Financing Activities for the year ending July 31, 2020 was USD 73.21 M, a 454.24% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Healthcare
Industries Biotechnology

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years